Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HLX01 in B-cell Lymphomas
NCT03218072Phase 1Completed
- Sponsor
- Henlius
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of rituximab in B cell lymphoma (3 arms), sponsored by Henlius. Primary endpoints: Adverse Events at Day 90 and Serious Adverse Events at Day 90. Started May 2014; status: completed.
02
Drugs
rituximab
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03218072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03218072.